146 related articles for article (PubMed ID: 37726872)
1. Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.
Scott EN; Joseph AA; Dhanda A; Tanoshima R; Brooks B; Rassekh SR; Ross CJD; Carleton BC; Loucks CM
Ther Drug Monit; 2023 Dec; 45(6):714-730. PubMed ID: 37726872
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
3. Further Investigation of the Role of
Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
[No Abstract] [Full Text] [Related]
4. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
5. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced ototoxicity: a novel approach to an ancient problem.
Omar NE; Elewa H
Pharmacogenet Genomics; 2023 Jul; 33(5):111-115. PubMed ID: 37068004
[TBL] [Abstract][Full Text] [Related]
9. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
12. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
Clemens E; Broer L; Langer T; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Byrne J; Broeder EVD; Crocco M; Grabow D; Kaatsch P; Kaiser M; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Kuehni CE; van der Pal H; Parfitt R; Deuster D; Matulat P; Spix C; Tillmanns A; Tissing WJE; Maier L; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM;
Pharmacogenomics J; 2020 Apr; 20(2):294-305. PubMed ID: 31666714
[TBL] [Abstract][Full Text] [Related]
14. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
[TBL] [Abstract][Full Text] [Related]
15. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F; Mitton C; Rassekh R; Brooks B; Ross C; Hayden M; Carleton B
Pharmacogenomics J; 2012 Jun; 12(3):205-13. PubMed ID: 21502965
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
Lanvers-Kaminsky C; Ciarimboli G
Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of cisplatin-induced ototoxicity.
Mukherjea D; Rybak LP
Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.
Drögemöller BI; Wright GEB; Lo C; Le T; Brooks B; Bhavsar AP; Rassekh SR; Ross CJD; Carleton BC
Clin Pharmacol Ther; 2019 Aug; 106(2):350-359. PubMed ID: 31012503
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
Tan WJT; Vlajkovic SM
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
